SCHEMBL5452622

SCHEMBL5452622

Nc1cccc(Oc2cc(-c3ncno3)ncn2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MAOB P27338 2/20 0.41
POLB P06746 1/20 0.37
HSP90AA1 P07900 1/20 0.37
MAPT P10636 1/20 0.37
ROCK1 Q13464 1/20 0.36
EGFR P00533 1/20 0.36
ERBB2 P04626 1/20 0.36
CYP3A4 P08684 2/20 0.36
TP53 P04637 1/20 0.36
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
BRCA1 P38398 1/20 0.35
HBB P68871 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5460155 0.85 SMN1; SMN2 (0.44) NPC1CYP1A2CYP2C9CYP2C19RAB9A
SCHEMBL14447569 0.85 SMN1; SMN2 (0.62) NPC1CYP1A2CYP2C9CYP2C19RAB9A
SCHEMBL5317914 0.83 CYP1A2 (0.43) NPC1CYP1A2CYP2C9CYP2C19RAB9A
SCHEMBL5379857 0.81 NPC1 (0.43) NPC1CYP1A2CYP2C9CYP2C19RAB9A
SCHEMBL5437209 0.80 NPC1 (0.43) NPC1CYP1A2CYP2C9CYP2C19RAB9A
SCHEMBL5340860 0.80 NPC1 (0.43) NPC1CYP1A2CYP2C9CYP2C19RAB9A
SCHEMBL5332692 0.77 MAP2K7 (0.46) NPC1CYP1A2CYP2C9CYP2C19RAB9A
SCHEMBL5347158 0.75 NPC1 (0.43) NPC1CYP1A2CYP2C9CYP2C19RAB9A
SCHEMBL5347932 0.75 ENPP2 (0.52) NPC1CYP1A2CYP2C9CYP2C19RAB9A
SCHEMBL5339167 0.74 ALDH1A1 (0.42) NPC1CYP1A2CYP2C9CYP2C19RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES BRAF, ARAF, RAF1 NPC1 4325/4885CYP1A2 4043/4885CYP2C9 3894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.